Jeffrey Low, MD, serves as Principal for Growth Investments at Novo Holdings US and holds board positions at Verana Health and Exscientia, in addition to being a Series A Investor in Erasca, Inc. Previously, Jeffrey Low was a Deal Partner at Andreessen Horowitz's Bio Fund and began experience as a Deal Team Intern there. Educational credentials include a medical degree from Yale School of Medicine and an MBA from Harvard Business School.